Web Stats Provided By Google Analytics

The Raw Stem Cell News Feed

The Stem Cell Research Newswire: Comprehensive Real-Time News Feed for Stem Cell Research

Tuesday, April 21, 2015

Pfizer's Inotuzumab Ozogamicin Phase 3 Study Meets Primary Endpoint

Pfizer today announced that the Phase 3 study investigating the treatment of inotuzumab ozogamicin met its first primary endpoint of demonstrating a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia compared to that achieved with standard of care chemotherapy. The Phase 3 study has two primary endpoints, complete hematologic remission rate and overall survival.
http://ift.tt/1HeNkNh

No comments:

Post a Comment

Popular Stem Cell Roundup Posts